Summary Cyclic adenosine 5¢diphosphate-ribose (cADPR) is thought to have a second messenger role in insulin secretion through mobilisation of Ca 2 + . As human lymphocyte antigen CD38 has both ADP-ribosyl cyclase and cADPR hydrolase activity, it may be important in glucose-induced insulin secretion in islets. Thirty one randomly selected Japanese patients with Type II diabetes mellitus who had firstdegree and/or second-degree relative(s) with Type II diabetes mellitus were screened for mutations of this gene using single-stranded conformation polymorphism. Two variant patterns in exon 3 and exon 4 of the CD38 gene were identified. The variant in exon 3 resulted in an amino acid substitution from Arg 140 (CGG) to Trp (TGG). The Arg 140 Trp mutation was observed in 4 of 31 patients, and allele frequencies were significantly different in patients and the control subjects (p = 0.004). One patient with this mutation has two missense mutations on beta cell/liver glucose transporter (GLUT2) gene; her mother, who has impaired glucose tolerance, also has this mutation on the CD38 gene and one missense mutation on the GLUT2 gene. Enzyme activity studies using COS-7 cells expressing the Arg 140 Trp mutation showed a reduction in ADP-ribosyl cyclase and cADPR hydrolase activity of around 50 %. The Arg
140
Trp mutation on CD38 thus appears to contribute to the development of Type II diabetes mellitus via the impairment of glucose-induced insulin secretion in the presence of other genetic defects. [Diabetologia (1998) 41: 1024±1028] Keywords CD38 gene, susceptibility, missense mutation, Type II diabetes mellitus, cyclic ADP-ribose, ADP-ribosyl cyclase, cyclic ADP-ribose hydrolase pared it with that of the microsomes of normal beta cells such as C57BL/6J mouse islets. We found that the Ca 2 + release responses of these diabetic beta cell microsomes were quite different from those of normal islet microsomes [11, 12] . Microsomes from C57BL/6J mouse islets, as well as Wistar rat islets, released Ca 2 + in response to cADPR, but showed a minimal response to IP 3 . In contrast to normal islet microsomes, ob/ob mouse islet microsomes were induced to release only a small amount of Ca 2 + by cADPR, but much more by IP 3 . RINm5F cell microsomes released appreciable Ca 2 + in response to IP 3 , but did not respond to cADPR. cADPR may therefore have a second messenger role in insulin secretion by mobilising Ca 2 + in normal beta cells, but not in diabetic beta cells.
Human lymphocyte antigen CD38 has been shown to have both ADP-ribosyl cyclase and cADPR hydrolase activities [16] , and is expressed in a variety of tissues and cells, including pancreatic islets [17] . Adenosine triphosphate (ATP), which is generated during glucose metabolism in islets, inhibits the cADPR hydrolase activity of CD38, thereby resulting in an accumulation of cADPR [16] . Moreover, glucose-induced insulin secretion is enhanced in transgenic mice overexpressing the CD38 in pancreatic beta cells [18] . Thus, CD38 is thought to have an important role in glucose-induced insulin secretion in islets. To investigate whether specific CD38 variants are associated with Type II diabetes mellitus, we analysed the CD38 gene in 31 Japanese subjects with Type II diabetes mellitus who had first-degree and/or second-degree relative(s) with Type II diabetes. We examined both ADP-ribosyl cyclase and cADPR hydrolase activities of the mutated CD38 detected in the patients.
Subjects and methods
Protocol 1. Thirty-one unrelated outpatients with Type II diabetes mellitus who had first-degree and/or second-degree relative(s) with Type II diabetes mellitus were randomly selected at Chiba University Hospital (Table 1 ). These patients were screened for mutations throughout the whole coding region of CD38. Ninety non-diabetic subjects with no family history of diabetes and normal glucose tolerance after administration of a 75 g oral glucose tolerance test were used as control subjects. The diagnosis of Type II diabetes mellitus was based on WHO criteria [19] . All patients and control subjects were informed of the purpose of the study, and their consent was obtained. This study was approved by the ethics committee of Chiba University Hospital and was performed in accordance with the Helsinki Declaration of 1975.
Screening for mutations in the CD38 cDNA. DNA was isolated from peripheral white blood cells by the phenol/chloroform method after digestion with proteinase K [20] . The eight exons and adjacent introns of CD38 [21] were amplified using primers specific for each exon ( Table 2 ). The polymerase chain reaction (PCR) was carried out in a volume of 5 ml containing 50 ng of genomic DNA, 0.1 U of Taq DNA polymerase (Takara, Otsu, Japan), 10 mmol/l of Tris-HCl pH 8.3, 50 mmol/l of KCl, 1.5 mmol/l of MgCl 2 , 100 mmol/l of dNTP with 10 pmol of 32 P-labelled specific primers. The PCR conditions were initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation at 94°C for 0.5 min, annealing at 50°C for 1 min and extension at 72°C for 2.5 min, with a final extension of 10 min. The PCR products were diluted 15 fold with formamide buffer (95 % formamide, 0.05 % bromphenol blue, and 0.05 % xylene cyanol), heated at 95°C for 3 min, and 1.5 ml of each sample were loaded onto a 5 % non-denaturing polyacrylamide gel (30´40´0.03 cm; acrylamide: N, N¢-methylene-bisacrylamide = 49:1). Each sample was run on four gels containing 0 % or 5 % glycerol at a room temperature or 4°C. The gels were then transferred to paper, dried and exposed to film with an intensifying screen for 12 h at ±70°C. The sequences of new bands observed by single-stranded conformation polymorphism were determined using phage vector M13.
Protocol 2: Mutagenesis and expression of CD38. CD38 exon 3, carrying the mutation (Arg 140 Trp), and adjacent introns were amplified by PCR from the genomic DNA of the patient. The fragment was subcloned using a kit (pCR-Script Amp SK( + ) 
Cloning Kit, Stratagene Cloning Systems, LaJolla, Calif., USA), and plasmids carrying the mutant allele were determined by DNA sequencing. An Eco RI-Bgl II fragment with the mutation was substituted for the normal fragment in an expression vector (pSV2-CD38). The identity of the gene was confirmed by DNA sequencing. The pSV2 vector carrying either the wild type or mutant human CD38 cDNA was introduced and expressed in COS-7 cells as described [16, 22, 23] .
Western blot analysis. Western blot analysis was carried out using an ECL detection system (Amersham Life Science, Buckinghamshire, UK) as described previously [16, 22, 23] . Blots were probed with the T16 [16, 22±24] (Cosmo Bio Co., Ltd., Tokyo, Japan) monoclonal antibody against human CD38. The band intensity of the expressed CD38 protein was measured using NIH Image software (version 1.57).
Enzyme assays. ADP-ribosyl cyclase and cADPR hydrolase assays were performed as described [16, 22, 23] [16, 22, 23] for assessing cADPR hydrolase. Reaction products were analysed by high performance liquid chromatography [16, 22, 23 ] using a flow scintillation analyser (FlowOne Beta-525TR, Packard, Meriden, Conn., USA). The protein concentration was measured by the method of Bradford [25] using bovine serum albumin as a standard.
Statistical analysis. The association of polymorphisms with Type II diabetes mellitus was analysed by 2´2 contingency tables and the significance of differences was tested by Fisher's exact test. Results are presented as mean ± SEM.
Results
All eight exons of the CD38 gene [21] were amplified in 31 Type II diabetes mellitus patients and analysed by single-stranded conformation polymorphism. Two variant patterns were noted in exons 3 and 4 ( Fig. 1) . Sequence analysis showed that one of these variants was a silent mutation in the codon for Ile 168 from ATA to ATC (Fig. 2) . The second change resulted in an amino acid substitution in which Arg 140 (CGG) was replaced by Trp (TGG). We then tested 90 nondiabetic control subjects for the presence of these two variants. The frequency of the Ile 168 (ATC) allele was 16 % in both patients with Type II diabetes mellitus and control subjects. In contrast, heterozygous polymorphism of Arg 140 /Trp was observed in 4 of 31 Type II diabetes mellitus patients who had first-degree and/or second-degree relative(s) with Type II diabetes mellitus, but not in any of the control subjects, and the allele frequencies were significantly different between the 31 Type II diabetes mellitus patients and the control subjects (p = 0.004) ( Table 3) .
CD38 wild type and Arg 140 Trp mutated expression vectors were constructed and introduced into COS-7 cells, and ADP-ribosyl cyclase and cADPR hydrolase activities were then measured. The mean ADPribosyl cyclase and cADPR hydrolase activities of the wild type CD38 in the three experiments were 2.49 ± 0.44 nmol × min ±1 × mg protein ±1 and 10.99 ± 1.94 nmol × min ±1 × mg protein
±1
, respectively. ) than non-mutated CD38 (Fig. 3) . COS-7 homogenates into which the control vector (pSV2 vector) had been introduced exhibited no ADP-ribosyl cyclase, cADPR hydrolase, or NAD + -glycohydrolase activities.
Discussion
The appreciable reduction in both ADP-ribosyl cyclase and cADPR hydrolase activities caused by the Arg
140
Trp mutation in CD38 shows that this mutation could contribute to the impairment of insulin secretion in vivo in patients with Type II diabetes mellitus. cADPR is thought to have a second messenger role in insulin secretion through Ca 2 + mobilisation [10±12]. As CD38 has both ADP-ribosyl cyclase and cADPR hydrolase activities, and ATP inhibits the cADPR hydrolase activity [11, 26] , CD38 may regulate glucoseinduced insulin secretion in islets [11, 16±18] . Our expression study suggests that this mutation is involved in the development of Type II diabetes mellitus via the impairment of glucose-induced insulin secretion.
The exact biological effect of the Arg
Trp mutation on the function of CD38 is not known. Arg 140 is conserved between human CD38 and the homologous Aplysia ADP-ribosyl cyclases [17] . The charged R group of arginine has key roles in stabilisation of specific protein conformations via the formation of salt bonds. Mutation of Arg 140 to a Trp residue containing an aromatic ring would affect the stabilisation of CD38, possibly resulting in a reduction in enzymatic activity. According to a recent report [27] , the residue may be important for ligand binding, and thus, this mutation is predicted to affect CD38 activity.
The heterozygous carriers of the Arg
Trp mutation were found in the patients who had first-degree and/or second-degree relative(s) with Type II diabetes mellitus, and the allele frequencies were significantly different between the patients with family history of diabetes and the control subjects. Thus, this mutation is associated with Japanese Type II diabetes mellitus having a familial aggregation of this disease. Indeed, one patient with this mutation has the Val 101 Ile and Gly 519 Glu mutations on the beta cell/liver glucose transporter (GLUT2) gene, and her mother, with impaired glucose tolerance, has this mutation on the CD38 gene and the Val 101 Ile mutation on the GLUT2 gene [28] . In these patients, the decreased function of CD38 mutant may contribute to the impairment of the glucose-stimulated insulin secretion in association with the GLUT2 mutants. Segregation analysis of Type II diabetes mellitus has, for the most part, excluded the hypothesis that Type II diabetes mellitus is controlled by a single major gene Trp CD38 mutant (R140W-CD38). A. CD38 expression in COS-7 cells by Western blot analysis. Lanes 1, 4 and 7; homogenates of COS-7 cells into which pSV2 vector had been introduced. Lane 2, 5 and 8; homogenates of COS-7 cells into which wild type CD38 expression vector had been introduced. Lane 3, 6 and 9; homogenates of COS-7 cells into which mutant CD38 expression vector had been introduced. B. ADP-ribosyl cyclase (solid bar) and cAD-PR hydrolase (hatched bar) activities were measured in COS-7 homogenates. Results are the mean ± SEM of three independent experiments Wild-CD38 R140W-CD38 [29] . The Arg 140 Trp mutation on CD38 gene may contribute to the development of Type II diabetes mellitus in the presence of other genetic defects in beta cell function and insulin action.
